Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 6/20 | 0.56 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.37 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.34 |
| ▸ | ITGAV | P06756 | 1/20 | 0.34 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2715722 | 1.00 | ACE (0.56) | ACEITGB1ITGA5ITGB3ITGAV | |
| SCHEMBL2712732 | 1.00 | ACE (0.56) | ACEITGB1ITGA5ITGB3ITGAV | |
| SCHEMBL29880999 | 0.88 | ACE (0.45) | ACEITGB1ITGA5ITGB3ITGAV | |
| SCHEMBL4709634 | 0.88 | ACE (0.45) | ACEITGB1ITGA5ITGB3ITGAV | |
| SCHEMBL4709631 | 0.88 | ACE (0.45) | ACEITGB1ITGA5ITGB3ITGAV | |
| SCHEMBL17979454 | 0.88 | ACE (0.45) | ACEITGB1ITGA5ITGB3ITGAV | |
| SCHEMBL30317311 | 0.83 | ACE (0.57) | ACEITGB1ITGA5ITGB3ITGAV | |
| SCHEMBL6899829 | 0.83 | ACE (0.57) | ACEITGB1ITGA5ITGB3ITGAV | |
| SCHEMBL8213582 | 0.83 | ACE (0.53) | ACEITGB1ITGA5ITGB3ITGAV | |
| SCHEMBL6899827 | 0.83 | ACE (0.57) | ACEITGB1ITGA5ITGB3ITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114920771-A | Novel synthesis process of intermediate of novel oral medicine for overactive bladder | 苏州虞美景盛新药开发有限公司 | 2022-08-19 | — | — | CN | claimed |
| US-8968711-B2 | Cosmetic or dermatological composition comprising a polymer bearing junction groups, and cosmetic treatment process | L'OREAL (FR) | 2015-03-03 | — | — | US | claimed |
| US-20100272660-A1 | COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT | L'OREAL (FR) | 2010-10-28 | — | — | US | claimed |
| US-20100239509-A1 | COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS | L'OREAL (FR) | 2010-09-23 | — | — | US | claimed |
| CN-114585637-B | MASP-inhibitory compounds and uses thereof | 拜耳公司 | 2025-04-15 | — | — | CN | disclosed |
| WO-2025076476-A2 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-04-10 | — | — | WO | disclosed |
| US-20240228506-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-07-11 | — | — | US | disclosed |
| WO-2024131827-A1 | KRAS G12D INHIBITORS AND USES THEREOF | 上海和誉生物医药科技有限公司 | 2024-06-27 | — | — | WO | disclosed |
| US-20240199647-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-06-20 | — | — | US | disclosed |
| CN-118215652-A | Substituted hydroxymethyl pyrrolidines and medical uses thereof | 阿托基公司 | 2024-06-18 | — | — | CN | disclosed |
| WO-2024123102-A1 | NOVEL TRICYCLIC COMPOUND AS KRAS G12D INHIBITOR, AND USE THEREOF | 에스케이바이오팜 주식회사 | 2024-06-13 | — | — | WO | disclosed |
| US-11993600-B2 | Saturated spirocyclics as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| US-20050059724-A1 | Novel cyanopyrrolidides, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-03-17 | — | — | US | disclosed |
| WO-2004052850-A2 | METHODS AND COMPOUNDS PRODUCING DIPEPTIDYL PEPTIDASE IV INHIBITORS AND INTERMEDIATES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-06-24 | — | — | WO | disclosed |
| US-6653295-B2 | Protease inhibitor; viricide | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-25 | — | — | US | disclosed |
| US-20030064962-A1 | Inhibitors of hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB COMPANY (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) | 2003-04-03 | — | — | US | disclosed |
| EP-1083897-A4 | HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2003-01-02 | — | — | EP | disclosed |
| US-6306891-B1 | INHIBITORS OF HIV INTEGRASE AND INHIBITORS OF HIV REPLICATION. THESE COMPOUNDS ARE USEFUL IN THE PREVENTION OR TREATMENT OF INFECTION BY HIV TREATMENT OF AIDS, EITHER AS COMPOUNDS, PHARMACEUTICALLY ACCEPTABLE SALTS | MERCK & CO., INC. | 2001-10-23 | — | — | US | disclosed |
| EP-1083897-A1 | HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2001-03-21 | — | — | EP | disclosed |
| WO-1999062513-A1 | HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 1999-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11993600-B2 | Saturated spirocyclics as antiviral agents | ACE, ACE2, PKD1 | ACE 1/4885ITGB1 4082/4885ITGA5 4047/4885 |
| US-20240228506-A1 | RIPK1 INHIBITORS AND METHODS OF USE | RIPK1, RIPK2, RIPK3 | ACE 3379/4885ITGB1 4515/4885ITGA5 4775/4885 |
| US-20050059724-A1 | Novel cyanopyrrolidides, process for their preparation and their use as medicaments | CYP11B2, SLC5A2, CYP11B1 | ACE 206/4885ITGB1 3655/4885ITGA5 3470/4885 |
| US-20030064962-A1 | Inhibitors of hepatitis C virus NS3 protease | PRSS1, SERPINB1, SPINT2 | ACE 42/4885ITGB1 3688/4885ITGA5 4249/4885 |
| US-20100239509-A1 | COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS | CUTA, SUCLG1, KRT18 | ACE 4847/4885ITGB1 4531/4885ITGA5 3623/4885 |
| US-20100272660-A1 | COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT | ACMSD, CUTA, PCCA | ACE 4664/4885ITGB1 2837/4885ITGA5 2767/4885 |
| US-20240199647-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | ACE 7/4885ITGB1 4432/4885ITGA5 4623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.